A. Harper

Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss?

A. Astrup, T. Larsen, A. Harper, 2004, The Lancet.

Family and Population-Based Studies of Variation within the Ghrelin Receptor Locus in Relation to Measures of Obesity

T. Hansen, O. Pedersen, A. Astrup, 2010, PloS one.

Population pharmacokinetic model for human growth hormone in adult patients in chronic dialysis compared with healthy subjects.

T. Klitgaard, M. Lange, A. Harper, 2009, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

Pharmacokinetics and pharmacodynamics of growth hormone in patients on chronic haemodialysis compared with matched healthy subjects: an open, nonrandomized, parallel-group trial

I. Langbakke, T. Klitgaard, M. Lange, 2007, Clinical endocrinology.

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

A. Astrup, L. Niskanen, A. Rissanen, 2013, International Journal of Obesity.

Can we advise our obese patients to follow the Atkins diet?

A. Harper, A. Astrup, 2004, Obesity reviews : an official journal of the International Association for the Study of Obesity.

Increased satiety after intake of a chocolate milk drink compared with a carbonated beverage, but no difference in subsequent ad libitum lunch intake

A. Astrup, A. Flint, A. Harper, 2007, British Journal of Nutrition.

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

A. Astrup, L. Niskanen, A. Rissanen, 2011, International Journal of Obesity.

Effect of copper supplementation on indices of copper status and certain CVD risk markers in young healthy women

S. Bügel, M. Bonham, E. Rock, 2005, British Journal of Nutrition.

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide

A. Astrup, L. Niskanen, A. Rissanen, 2012, International Journal of Obesity.

Liraglutide, a once-daily human GLP-1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo-controlled trial

A. Astrup, L. Niskanen, A. Rissanen, 2009 .

ORIGINAL ARTICLE Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue

A. Astrup, L. Niskanen, M. Kunesova, 2012 .

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide (vol 36, pg 843, 2012)

A. Astrup, L. Niskanen, A. Rissanen, 2013 .